

Date: 11/12/2015

FREEDOM OF INFORMATION REQUEST FOI/012523 – Non small cell lung carcinoma

1. Within your health trust how many unique patients with Non-small-cell lung carcinoma [Stage IIIB/Stage IV] have been treated in the past 6 months?
46 unique patients treated by DGFT with stage IIIB or stage IV non small cell lung cancer (that is , anything but small cell lung cancer) between 1st May 2015 and 31st October 2015.
(stage IIIB being defined as T4 N2 M0 or T* N3 M0, stage IV as T* M1 disease)
<http://cancerstaging.org/references-tools/quickreferences/documents/lungmedium.pdf>

Of those patients please split by their current drug treatment;

Afatinib (Giotrif) - 1
Ceritinib (Zykadia) - 0
Crizotinib (Xalkori) - 0
Erlotinib (Tarceva) - 6
Gefitinib (Iressa) - 2
Nitendaniinb + docetaxel - 2
Pemetrexed (Alimta) - 23
Gemcitabine mono or in combination with carboplatin / cisplatin - 32
Paclitaxel mono or in combination with carboplatin / cisplatin - 0
Doxetaxel mono or in combination with carboplatin / cisplatin - 8
Vinorelbine [or other Vinka alkaloid] mono or in combination with carboplatin / cisplatin - 2
Other

2. Does your trust carry out EGFR [Epidermal Growth Factor Receptor] tests in house or in a named reference centre

Samples are sent to QE, Birmingham

3. Within your trust how many unique patients with Advanced Prostate Cancer have been treated in the past 6 months?

The Trust is unable to determine from data the staging of the prostate patients as this is not routinely recorded by the Urologists. Therefore we are unable to give any further information other than what pharmacy have provided below.

How many patients with Advanced Prostate Cancer have received ;

Abiraterone (Zytiga) - 18
Cabazitaxel (Jevtana) - 5
Docetaxel (Taxotere) - 12
Enzalutamide (Xtandi) - 17
Radium-223 (Xofigo) - 0

If your trust is unable to identify patients by the condition and treatment, please supply all patients for treatment, regardless of conditi